GlassScriptPhysician profile
Oscar C Munoz
NPI 1538274824
$30,023.62
in general payments reported to CMS, 2019-2025
43 companies · $2,608 in 2025
The $2,608 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $2,300 · 2021: $4,787 · 2022: $1,869 · 2023: $2,103 · 2024: $1,734 · 2025: $2,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,370 · Debt Forgiveness: $74.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,370.11 |
| Debt Forgiveness | $74.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $12,148.15 | 2019-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $3,158.50 | 2021-2025 | Micra, Endurant Iis, Cobalt Dr Mri Surescan |
| Pfizer INC. | $2,987.22 | 2019-2025 | |
| Abbott Laboratories | $2,863.12 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Navitor |
| Medtronic Vascular, INC. | $1,666.24 | 2019-2020 | |
| Boston Scientific Corporation | $750.00 | 2019-2025 | General - Therapies, General - Tachy, Eluvia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $731.69 | 2019-2025 | Jardiance |
| Abiomed | $703.87 | 2019-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $613.55 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $517.74 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Elutia, INC. | $451.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $450.13 | 2019-2024 | Xarelto |
| Amgen INC. | $409.61 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $339.56 | 2019-2024 | (5091) Amb Mon & Diag Und |
| Edwards Lifesciences Corporation | $267.24 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $262.47 | 2020-2025 | Lifevest |
| Bard Peripheral Vascular, INC. | $190.05 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $179.45 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $166.69 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.40 | 2025 | |
| Alkermes, INC. | $105.89 | 2025 | Aristada, Aristada Initio |
| Lexicon Pharmaceuticals, INC. | $93.34 | 2023-2024 | Inpefa |
| Becton, Dickinson and Company | $85.24 | 2024-2025 | Ultrascore, Powerpicc, True Dilatation |
| Chiesi USA, INC. | $74.72 | 2019-2021 | |
| Baxter Healthcare | $74.48 | 2025 | |
| Scpharmaceuticals INC. | $57.49 | 2023-2024 | |
| Novo Nordisk INC | $57.06 | 2020-2025 | Wegovy |
| W. L. Gore & Associates, INC. | $55.68 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Amarin Pharma, INC. | $54.32 | 2019-2020 | |
| Gilead Sciences, INC. | $52.05 | 2019 | |
| Tactile Systems Technology INC | $39.91 | 2019-2020 | |
| Cvrx, INC. | $38.30 | 2025 | Barostim Neo System |
| Allergan, INC. | $38.19 | 2019 | |
| Alnylam Pharmaceuticals INC. | $37.25 | 2025 | Amvuttra |
| Convatec INC. | $23.70 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $23.11 | 2025 | Uptravi, Opsumit |
| Angiodynamics, INC. | $20.69 | 2020 | |
| Astellas Pharma US INC | $18.71 | 2019 | |
| Bridgebio Pharma, INC. | $17.80 | 2025 | Attruby |
| Genzyme Corporation | $17.32 | 2019 | |
| Biocompatibles, INC. | $15.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.52 | 2019 | |
| Thrombolex, INC. | $10.56 | 2025 | Bashir Endovascular Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.